CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

0 Comments | | Return |

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications


Updated Sample Acceptability Document

CTS was recently notified that one of the tubes listed in the Sample Acceptability document...

Read More >

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 conva...

Read More >

National Blood Donor Month

Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...

Read More >

Seasonal Monitoring for WNV to begin June 1, 2019

Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...

Read More >

National Blood Donor Month

National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...

Read More >

Subscribe here to receive CTS updates!